
Sam is currently CSO of Psylo; a biotech start-up focused on the development of next-generation psychedelic medicines. Sam has been developing new therapeutics in the fields of neuropsychiatry and neurology for more than 15 years at leading academic institutions (Stanford University, University of Sydney, UNSW) and biotech start-ups (Tranquis Therapeutics, NaluBio). Prior to founding Psylo, he was Team Leader in Medicinal Chemistry at The Lambert Initiative for Cannabinoid Therapeutics, and was a postdoc at Stanford University studying cannabinoids, psychedelics, and new psychoactive substances (NPS) before that.
His work on the chemistry and pharmacology of new psychoactive substances (sometimes called "research chemicals") has been covered by major newspapers (New York Times, Sydney Morning Herald) and national radio programs (NPR). Sam is an enthusiastic science communicator, appearing as a guest on numerous science podcasts, and regularly presents at community science events such as Pint of Science, National Science Week, Vivid, and The Science Tent at Splendour in the Grass.